GlaxoSmithKline PLC, Johnson & Johnson Private Limited, Bausch Health Companies Inc., Cipla Limited, and 3M Company. Topical Drug Delivery Market Segment Analysis Based on the research, Verified ...

NEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2024 and raised full year 2024 guidance for Portfolio Receipts. ...

Luxury fashion and lifestyle group Kering, pharma giant GSK and building materials producer Holcim have become the first ...

Sales of GSK’s top-selling vaccines fell sharply during the third quarter amid lower demand, sending shares in the British pharmaceutical company down 3% in U.S. trading Wednesday. GSK, which had ...

Oct 29 (Reuters) - India's GlaxoSmithKline Pharmaceuticals (GLAX.NS), opens new tab reported a higher second-quarter adjusted profit on Tuesday, driven by strong demand for its generic drugs and ...

"GSK recognizes Ontario's leadership in expanding its first-in-Canada RSV program for older adults to include additional ...

GSK said it is mak­ing its largest man­u­fac­tur­ing in­vest­ment in the US yet, al­lo­cat­ing $800 mil­lion to up­grade its vac­cine pro­duc­tion site in Penn­syl­va­nia. … ...

GSK has made its largest-ever single manufacturing investment in the US. Image credit: Shutterstock/ Golden Shrimp. Following outlays for sites in the UK and Belgium earlier this year, GSK is planning ...

THE ARM FOR THE LANCASTER COUNTY ECONOMY. THIS IS FOR GSK, THE LARGEST INVESTMENT IN MANUFACTURING WE’VE EVER DONE IN THE UNITED STATES. THE $800 MILLION WILL BE USED TO EXPAND GSK’S MARIETTA ...

After making a splash in the U.K. earlier this year, GSK is laying out plans for its biggest U.S. manufacturing investment yet. GSK is investing up to $800 million to double the size and capacity ...

Preliminary results from two trials showed that GSK’s respiratory syncytial virus (RSV) vaccine Arexvy has potential in younger adults with certain risk factors, potentially positioning the shot ...